Hisashi Nakayama

Prof. Dr. Hisashi Nakayama

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2021 in Liver Cancer
Verified
Journal Article
Open access
PDF file
TTTadatoshi Takayama
Tadatoshi Takayama
KHKiyoshi Hasegawa
Kiyoshi Hasegawa
NINamiki Izumi
Namiki Izumi
Masatoshi KudoMasatoshi Kudo
Masatoshi Kudo
MSMitsuo Shimada
Mitsuo Shimada
NKNorihiro Kokudo
Norihiro Kokudo
Introduction: It remains unclear which surgery or radiofrequency ablation (RFA) is the more effective treatment for small hepatocellular carcinoma (HCC). We aimed to compare survival between patients undergoing surgery (surgery group) and patients undergoing RFA (RFA group). Methods: We conducted a randomized controlled trial involving 49 institutions in Japan. Patients with Child-Pugh scores ≤7, largest HCC diameter ≤3 cm, and ≤3 HCC nodules were considered eligible. The co-primary endpoints were recurrence-free survival (RFS) and overall survival (OS). The current study reports the final result of RFS, and the follow-up of OS is still ongoing. Results: During 2009–2015, 308 patients were registered. After excluding ineligible patients, the surgery and RFA groups included 150 and 151 patients, respectively. Baseline factors did not differ significantly between the groups. In both groups, 90% of patients had solitary HCC. The median largest HCC diameter was 1.8 cm (interquartile range [IQR], 1.5–2.2 cm) in the surgery group and 1.8 cm (IQR, 1.5–2.3 cm) in the RFA group. The median procedure duration (274 vs. 40 min, p < 0.01) and the median duration of hospital stay (17 days vs. 10 days, p < 0.01) were longer in the surgery group than in the RFA group. RFS did not differ significantly between the groups as the median RFS was 3.5 (95% confidence interval [CI], 2.6–5.1) years in the surgery group and 3.0 (95% CI, 2.4–5.6) years in the RFA group (hazard ratio, 0.92; 95% CI, 0.67–1.25; p = 0.58). Discussion/Conclusion: Our study did not show which surgery or RFA is the better treatment option for small HCC.

13 June 2022 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
TOTakehito Otsubo
Takehito Otsubo
SKShinjiro Kobayashi
Shinjiro Kobayashi
KSKeiji Sano
Keiji Sano
TMTakeyuki Misawa
Takeyuki Misawa
SKSatoshi Katagiri
Satoshi Katagiri
IEItaru Endo
Itaru Endo

12 February 2014 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
HNHisashi Nakayama
Hisashi Nakayama
TTTadatoshi Takayama
Tadatoshi Takayama
TOTakao Okubo
Takao Okubo
THTokio Higaki
Tokio Higaki
YMYutaka Midorikawa
Yutaka Midorikawa
SYShintaro Yamazaki
Shintaro Yamazaki

2 January 2023 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
HNHisashi Nakayama
Hisashi Nakayama
YOYukiyasu Okamura
Yukiyasu Okamura
THTokio Higaki
Tokio Higaki
MMMasamichi Moriguchi
Masamichi Moriguchi
TTTadatoshi Takayama
Tadatoshi Takayama

1 January 2018 in BioScience Trends
Verified
Journal Article
Open access
PDF file
THTokio Higaki
Tokio Higaki
OAOsamu Aramaki
Osamu Aramaki
MMMasamichi Moriguchi
Masamichi Moriguchi
HNHisashi Nakayama
Hisashi Nakayama
YMYutaka Midorikawa
Yutaka Midorikawa
TTTadatoshi Takayama
Tadatoshi Takayama
Conventional regimens for unresectable intrahepatic cholangiocarcinoma are considered of limited effectiveness. To evaluate the efficacy and toxicity of combination chemotherapy with hepatic arterial infusion of IA-call (a fine-powder formulation of cisplatin) plus oral S-1 in patients with unresectable intrahepatic cholangiocarcinoma. The clinicopathological data and long-term outcome of 12 patients who were received with IA-call plus S-1 were compared with those of 16 patients who were received other treatments, such as radiation therapy, trans-arterial chemoembolization, and systemic chemotherapy. The IA-call plus S-1 regimen consisted of IA-call (65 mg/m2, administered into the hepatic artery) on day 1 and oral S-1 (60 mg/m2/day) on days 1-28, every 42 days, repeated cycle. Prognostic factors of these patients were evaluated by uni- and multivariate analysis. There was no significant difference between the two groups in the disease status, such as the number of tumor and the tumor size. The overall survival was significantly longer in the patients receiving the arterial IA-call and S-1 regimen (median survival time = 10.1; range, 3.6-24.2 months) than in the receiving other treatments (median survival time = 4.0; range; 0.3-24.2 months, p = 0.01). The multivariate analysis revealed that chemotherapy regimen was significantly related to survival, with a hazard ratio of 3.97 (p = 0.02). In the IA-call plus S-1 group, the overall response rate was 33.3%. The major toxic effect was grade 3 anemia, occurring in 1 patient (4.5%). Combination chemotherapy with arterial IA-call plus oral S-1 is an effective regimen that may improve survival in patients with unresectable intrahepatic cholangiocarcinoma.

1 January 2015 in World Journal of Hepatology
Verified
Journal Article
Open access
HNHisashi Nakayama
Hisashi Nakayama
TTTadatoshi Takayama
Tadatoshi Takayama
Management before hepatectomy for hepatocellular carcinoma with cirrhosis